Ethical considerations explored for aducanumab in Alzheimer’s disease
Nov 19, 2021
Grounds are insufficient to offer aducanumab (Aduhelm) for moderate, advanced Alzheimer’s dementia or for individuals without biomarker evidence of brain ß-amyloid, according to a position statement.
AAN issues review of evidence for aducanumab in Alzheimer’s disease
Mar 03, 2022
A class I study shows that single doses of aducanumab are safe and well-tolerated; class II studies show reduced amyloid deposition on brain PET at one year.
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).
Expert panel publishes first recommendations on appropriate use of Alzhemier’s drug Aduhelm
By
Kimberly Bonvissuto
Jul 27, 2021
A panel of experts in the Alzheimer’s field this morning published the first recommendations for the appropriate use of aducanumab (Aduhelm), the controversial new drug to treat early, mild disease.
FDA approves first treatment for Alzheimer’s in 18 years
By
Kimberly Bonvissuto
Jun 07, 2021
The first novel therapy for Alzheimer’s disease in almost two decades was approved today by the Food & Drug Administration.
House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
The FDA approved aducanumab earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness.
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.
Two Alzheimer’s drug trials halted
By
Lois A. Bowers
Mar 22, 2019
Two late-stage clinical trials of a drug for Alzheimer’s disease have been stopped because they aren’t likely to produce promising results, two companies involved with the research announced Thursday.
Focus on briefs: Dementia
Feb 01, 2023
Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s